Linagliptin/Metformin Stada

Linagliptin/Metformin, the active ingredient in Linagliptin/Metformin Stada, is a DPP‑4 inhibitor; Biguanide presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, improving blood glucose control when combined with diet, exercise, and other antidiabetic agents as needed.

GNH USA supplies Linagliptin/Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Linagliptin/Metformin is used in the treatment of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

- Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise. - Postprandial hyperglycemia: reduces post‑meal glucose excursions by enhancing insulin secretion. - Combination therapy: can be combined with insulin or other oral antidiabetics to achieve target HbA1c. - Metabolic syndrome with elevated glucose: assists in lowering fasting plasma glucose levels.

Linagliptin/Metformin may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, usually transient. - Headache: mild cranial discomfort. - Upper respiratory tract infection: symptoms such as sore throat or runny nose. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Allergic reactions: rash, angioedema, or anaphylaxis.

Before prescribing Linagliptin/Metformin, clinicians should consider several safety precautions. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic function: monitor liver enzymes in patients with existing liver disease. - Lactic acidosis risk: discontinue if signs of metabolic acidosis appear. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Concomitant sulfonylureas or insulin: monitor for hypoglycemia and adjust dose accordingly. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Linagliptin/Metformin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Rifampicin: induces metabolism, reducing linagliptin levels. - Cimetidine: impairs metformin renal clearance, raising risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): may affect renal function and metformin elimination. - ACE inhibitors or ARBs: combined use can increase risk of renal impairment. - Thyroid hormones: may alter glycemic control, requiring dose adjustment.